EZH2 and cancer: demonstrated that SWI/SNF-mutant cancers (including those with SMARCA4/BRG1 mutations) typically show increased sensitivity to EZH2 inhibitors (20), suggesting that the combination of BRG-1 deficiency and KRAS mutation may not only alter signaling pathways and immunological characteristics but also create specific vulnerabilities that can be therapeutically exploited.